Harlan Robins Sells 6,160 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Harlan Robins sold 6,160 shares of Adaptive Biotechnologies stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $18.01, for a total value of $110,941.60. Following the transaction, the insider directly owned 1,405,898 shares of the company’s stock, valued at approximately $25,320,222.98. The trade was a 0.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Adaptive Biotechnologies Stock Performance

Shares of NASDAQ ADPT traded down $0.44 during midday trading on Wednesday, reaching $16.78. 13,515,842 shares of the company traded hands, compared to its average volume of 2,445,506. The firm has a market cap of $2.69 billion, a PE ratio of -50.85 and a beta of 2.15. The stock’s 50-day simple moving average is $14.72 and its 200-day simple moving average is $15.59. Adaptive Biotechnologies Corporation has a 12 month low of $9.96 and a 12 month high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. The company had revenue of $70.87 million during the quarter, compared to analysts’ expectations of $61.03 million. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The business’s revenue was up 35.1% on a year-over-year basis. During the same period last year, the business earned ($0.20) earnings per share. On average, equities research analysts expect that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current year.

More Adaptive Biotechnologies News

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Negative Sentiment: Adaptive Biotechnologies priced an upsized $300 million offering of 0% convertible senior notes due 2031, which raises fresh capital but also signals potential dilution risk and added complexity for shareholders. The company plans to use the proceeds to repay the OrbiMed Purchase Agreement, fund capped call transactions, and repurchase $25 million of stock to help offset dilution. Article Title
• Negative Sentiment: Multiple insider sales were disclosed, including Chief Scientific Officer Harlan S. Robins selling 100,000 shares and another 6,160 shares under a 10b5-1 plan. While pre-planned, the volume of insider selling may reinforce caution around the stock. Article Title
• Neutral Sentiment: BTIG Research reaffirmed its Buy rating and kept a $22 price target, suggesting analysts still see meaningful upside from current levels. Article Title
• Neutral Sentiment: The company’s recent earnings trend remains supportive, with Q1 revenue up 35.1% year over year and results beating expectations, which helps offset some of the financing-related concerns.

Wall Street Analyst Weigh In

ADPT has been the subject of a number of research reports. Guggenheim restated a “buy” rating and issued a $21.00 target price on shares of Adaptive Biotechnologies in a research note on Wednesday, May 6th. Morgan Stanley lowered their target price on Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 12th. BTIG Research restated a “buy” rating and issued a $22.00 target price on shares of Adaptive Biotechnologies in a research note on Wednesday. Wall Street Zen lowered Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Monday, April 20th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $19.57.

Institutional Trading of Adaptive Biotechnologies

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd acquired a new stake in Adaptive Biotechnologies in the fourth quarter worth about $28,000. EverSource Wealth Advisors LLC increased its position in Adaptive Biotechnologies by 197.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after purchasing an additional 1,565 shares during the period. KBC Group NV acquired a new stake in Adaptive Biotechnologies in the first quarter worth about $45,000. Assetmark Inc. increased its position in Adaptive Biotechnologies by 867.9% in the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after purchasing an additional 2,708 shares during the period. Finally, T. Rowe Price Investment Management Inc. acquired a new stake in Adaptive Biotechnologies in the fourth quarter worth about $51,000. 99.17% of the stock is currently owned by institutional investors and hedge funds.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.